<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274857</url>
  </required_header>
  <id_info>
    <org_study_id>REAFFIRM</org_study_id>
    <nct_id>NCT02274857</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures</brief_title>
  <acronym>REAFFIRM</acronym>
  <official_title>Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures (REAFFIRM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multicenter, randomized study to assess the safety and
      effectiveness of FIRM procedures followed by conventional ablation including PVI versus a
      standard PVI procedure for the treatment of persistent atrial fibrillation (AF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">November 10, 2018</completion_date>
  <primary_completion_date type="Actual">November 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure</measure>
    <time_frame>Within 7-10 days of the Procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-procedure Freedom From AF/AT Recurrence at 3 Month Post Index Procedure.</measure>
    <time_frame>3-month follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-procedure Freedom From AF/AT Recurrence at 3 to 12 Months Post Index Procedure.</measure>
    <time_frame>3-12 months post study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From Procedure-related SAEs (Including Those Related to Any Repeat Procedures) Within 12-months of the Initial Procedure</measure>
    <time_frame>3 to 12 months post study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Acute Effectiveness of FIRM-guided Procedures in Eliminating the Source of Arrhythmia as Shown by: No Evidence of the Source in FIRMap Post-op, OR Reduction of Electrogram Amplitude to &lt; 0.2 Millivolts</measure>
    <time_frame>Immediately post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Standard PVI Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FIRM-guided Procedure and PVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FIRM-guided procedure followed by standard catheter ablation including PVI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard PVI Ablation</intervention_name>
    <description>Standard PVI procedure without FIRMap.</description>
    <arm_group_label>Standard PVI Ablation</arm_group_label>
    <other_name>Pulmonary vein isolation</other_name>
    <other_name>Ablation</other_name>
    <other_name>Arrhythmia</other_name>
    <other_name>Persistent atrial fibrillation</other_name>
    <other_name>Mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FIRM-Guided Procedure and PVI</intervention_name>
    <description>FIRM-guided procedure followed by conventional ablation including PVI.</description>
    <arm_group_label>FIRM-guided Procedure and PVI</arm_group_label>
    <other_name>Pulmonary vein isolation</other_name>
    <other_name>Ablation</other_name>
    <other_name>Arrhythmia</other_name>
    <other_name>Persistent atrial fibrillation</other_name>
    <other_name>Mapping</other_name>
    <other_name>FIRMap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  At least two (2) documented episodes of persistent atrial fibrillation during prior 3
             months

          -  Refractory, intolerant, or contraindicated to Class I or III anti-arrhythmic
             medications

          -  Left atrial diameter &lt; 6.0 cm

        Key Exclusion Criteria:

          -  Previous AF Ablation

          -  Presence of structural heart disease

          -  New York Heart Association (NYHA) Class IV.

          -  Ejection fraction &lt; 35%.

          -  History of myocardial infarction (MI) within the past three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Brachmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Coburg GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Heart Rhythm Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University - Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Minden-L체bbecke</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum f체r klinische Pr체fungen in der Facharztzentrum Dresden-Neustadt GbR</name>
      <address>
        <city>Dresden</city>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St채dtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Institute GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologische Gemeinschaftspraxis am Park Sanssouci</name>
      <address>
        <city>Potsdam</city>
        <zip>14471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <results_first_submitted>January 6, 2020</results_first_submitted>
  <results_first_submitted_qc>February 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 7, 2020</results_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Focal Impulse and Rotor Modulation Mapping Catheter (FIRMap)</keyword>
  <keyword>Rotor</keyword>
  <keyword>FIRM-guided procedure</keyword>
  <keyword>REAFFIRM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02274857/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 17, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02274857/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard PVI Ablation</title>
          <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent atrial fibrillation (AF).
Standard PVI Ablation: Standard PVI procedure without Focal Impulse and Rotor Modulation Mapping Catheter (FIRMap).</description>
        </group>
        <group group_id="P2">
          <title>FIRM-guided Procedure and PVI</title>
          <description>Focal Impulse and Rotor Modulation (FIRM)-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Per Protocol</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard PVI Ablation</title>
          <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
Standard PVI Ablation: Standard PVI procedure without FIRMap.</description>
        </group>
        <group group_id="B2">
          <title>FIRM-guided Procedure and PVI</title>
          <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="179"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="8.7"/>
                    <measurement group_id="B2" value="64.2" spread="8.4"/>
                    <measurement group_id="B3" value="63.4" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.12" spread="5.63"/>
                    <measurement group_id="B2" value="31.17" spread="5.59"/>
                    <measurement group_id="B3" value="31.15" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Classification</title>
          <description>The New York Heart Association Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina.
Class I = no limitation of physical activity. Class II = slight limitation Class III = marked limitation Class IV = unable to carry on any physical activity without discomfort.</description>
          <units>category</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Largest Left Atrial Diameter</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.63" spread="9.63"/>
                    <measurement group_id="B2" value="48.07" spread="7.65"/>
                    <measurement group_id="B3" value="46.82" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Ejection Fraction</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="8.9"/>
                    <measurement group_id="B2" value="53.8" spread="8.0"/>
                    <measurement group_id="B3" value="54.2" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior and concomitant antiarrhythmic drugs (AAD)</title>
          <description>Prior and concomitant use of AADs refers to the types of pharmacological therapies a participant has been on or is on in order to treat their arrhythmia. Participants may be on more than one type of AAD.
Class 1 AAD = Sodium Channel Blockers Class 2 AAD = Beta-Adrenoceptor Antagonist Class 3 AAD = Potassium Channel Blockers Class 4 AAD = Calcium Channel Blockers</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class I AAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class 2 AAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class 3 AAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class 4 AAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospitalizations for Cardiac Arrhythmias within 6 months of screening</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treated for atrial fibrillation in the 6 months prior to enrollment</title>
          <units>%</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.4"/>
                    <measurement group_id="B2" value="88.9"/>
                    <measurement group_id="B3" value="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of significant past and/or concomitant diseases or past surgeries</title>
          <units>%</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1"/>
                    <measurement group_id="B2" value="67.8"/>
                    <measurement group_id="B3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS/Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6"/>
                    <measurement group_id="B2" value="11.7"/>
                    <measurement group_id="B3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dermatologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0"/>
                    <measurement group_id="B2" value="4.7"/>
                    <measurement group_id="B3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug Allergy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4"/>
                    <measurement group_id="B2" value="1.8"/>
                    <measurement group_id="B3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine/Metabolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4"/>
                    <measurement group_id="B2" value="30.4"/>
                    <measurement group_id="B3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes/Ears/Nose/Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2"/>
                    <measurement group_id="B2" value="12.9"/>
                    <measurement group_id="B3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.4"/>
                    <measurement group_id="B2" value="23.4"/>
                    <measurement group_id="B3" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9"/>
                    <measurement group_id="B2" value="12.9"/>
                    <measurement group_id="B3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0"/>
                    <measurement group_id="B2" value="4.1"/>
                    <measurement group_id="B3" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2"/>
                    <measurement group_id="B2" value="2.9"/>
                    <measurement group_id="B3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9"/>
                    <measurement group_id="B2" value="4.7"/>
                    <measurement group_id="B3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6"/>
                    <measurement group_id="B2" value="5.3"/>
                    <measurement group_id="B3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3"/>
                    <measurement group_id="B2" value="28.1"/>
                    <measurement group_id="B3" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3"/>
                    <measurement group_id="B2" value="5.8"/>
                    <measurement group_id="B3" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9"/>
                    <measurement group_id="B2" value="11.1"/>
                    <measurement group_id="B3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0"/>
                    <measurement group_id="B2" value="22.8"/>
                    <measurement group_id="B3" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.2"/>
                    <measurement group_id="B2" value="26.3"/>
                    <measurement group_id="B3" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subjects that had LV Ejection Fraction Measured</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure</title>
        <time_frame>Within 7-10 days of the Procedure</time_frame>
        <population>Intent to Treat (ITT) group, defined as subject randomized to a treatment group who had a mapping and/or ablation catheter inserted</population>
        <group_list>
          <group group_id="O1">
            <title>Standard PVI Ablation</title>
            <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
Standard PVI Ablation: Standard PVI procedure without FIRMap.</description>
          </group>
          <group group_id="O2">
            <title>FIRM-guided Procedure and PVI</title>
            <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure</title>
          <population>Intent to Treat (ITT) group, defined as subject randomized to a treatment group who had a mapping and/or ablation catheter inserted</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2179</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single-procedure Freedom From AF/AT Recurrence at 3 Month Post Index Procedure.</title>
        <time_frame>3-month follow up</time_frame>
        <population>ITT: each subject randomized to a treatment group who had a mapping and/or ablation catheter inserted Per Protocol: those subjects in the ITT group who completed all follow-up visits and had no major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Standard PVI Ablation</title>
            <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
Standard PVI Ablation: Standard PVI procedure without FIRMap.</description>
          </group>
          <group group_id="O2">
            <title>FIRM-guided Procedure and PVI</title>
            <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
          </group>
        </group_list>
        <measure>
          <title>Single-procedure Freedom From AF/AT Recurrence at 3 Month Post Index Procedure.</title>
          <population>ITT: each subject randomized to a treatment group who had a mapping and/or ablation catheter inserted Per Protocol: those subjects in the ITT group who completed all follow-up visits and had no major protocol deviations</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2782</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single-procedure Freedom From AF/AT Recurrence at 3 to 12 Months Post Index Procedure.</title>
        <time_frame>3-12 months post study treatment</time_frame>
        <population>ITT group, defined as each subject randomized to a treatment group who had a mapping and/or ablation catheter inserted</population>
        <group_list>
          <group group_id="O1">
            <title>Standard PVI Ablation</title>
            <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
Standard PVI Ablation: Standard PVI procedure without FIRMap.</description>
          </group>
          <group group_id="O2">
            <title>FIRM-guided Procedure and PVI</title>
            <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
          </group>
        </group_list>
        <measure>
          <title>Single-procedure Freedom From AF/AT Recurrence at 3 to 12 Months Post Index Procedure.</title>
          <population>ITT group, defined as each subject randomized to a treatment group who had a mapping and/or ablation catheter inserted</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5"/>
                    <measurement group_id="O2" value="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7266</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Procedure-related SAEs (Including Those Related to Any Repeat Procedures) Within 12-months of the Initial Procedure</title>
        <time_frame>3 to 12 months post study treatment</time_frame>
        <population>ITT group, defined as each subject randomized to a treatment group who had a mapping and/or ablation catheter inserted</population>
        <group_list>
          <group group_id="O1">
            <title>Standard PVI Ablation</title>
            <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
Standard PVI Ablation: Standard PVI procedure without FIRMap.</description>
          </group>
          <group group_id="O2">
            <title>FIRM-guided Procedure and PVI</title>
            <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Procedure-related SAEs (Including Those Related to Any Repeat Procedures) Within 12-months of the Initial Procedure</title>
          <population>ITT group, defined as each subject randomized to a treatment group who had a mapping and/or ablation catheter inserted</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3522</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Acute Effectiveness of FIRM-guided Procedures in Eliminating the Source of Arrhythmia as Shown by: No Evidence of the Source in FIRMap Post-op, OR Reduction of Electrogram Amplitude to &lt; 0.2 Millivolts</title>
        <time_frame>Immediately post procedure</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>FIRM-guided Procedure and PVI</title>
            <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Acute Effectiveness of FIRM-guided Procedures in Eliminating the Source of Arrhythmia as Shown by: No Evidence of the Source in FIRMap Post-op, OR Reduction of Electrogram Amplitude to &lt; 0.2 Millivolts</title>
          <population>ITT</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" lower_limit="79.7" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard PVI Ablation</title>
          <description>Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
Standard PVI Ablation: Standard PVI procedure without FIRMap.</description>
        </group>
        <group group_id="E2">
          <title>FIRM-guided Procedure and PVI</title>
          <description>FIRM-guided procedure followed by standard catheter ablation including PVI.
FIRM-Guided Procedure and PVI: FIRM-guided procedure followed by conventional ablation including PVI.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pericarditis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pericardial disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pericardial hemmorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroparesis postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peritoneal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Vessel puncture site hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All manuscripts should be submitted to the sponsor for review and comment prior to submission to the publisher.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Program Director</name_or_title>
      <organization>Abbott</organization>
      <phone>651-756-6717</phone>
      <email>kristin.ruffner@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

